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conscious animals. The MAP values as well as left ventricular
dP/dt observed by Sun et al. using intermittent intravenous
pentobarbital anesthesia are, in fact, excessive when compared to
values reported in the literature for swine anesthetized with
pentobarbital (3). This suggests that the “control” values reported
by Sun et al. are supranormal, possibly reflecting enhanced sympa-
thetic tone of uncertain etiology. We would therefore agree with
Sun et al. that these differences of concern to them are due to
differences in experimental procedures between our laboratories.
However, they are not reflective of inadequate technical skills in
our laboratory used in the acquisition and interpretation of
hemodynamic data.
Our data do, in fact, support the observations of Sun et al. In a
prior publication (4), they reported no differences between defi-
brillation waveform groups with respect to first shock success or
clinically important indexes of postresuscitation cardiac function
after a 4-min period of ventricular fibrillation (VF). Observed
differences appear to resolve rather than evolve during extended
observation. Sun et al. have previously acknowledged the effect of
prolonged pentobarbital anesthesia on cardiac mechanics (5). We
likewise observed no differences during observation after a 5-min
VF period. It would appear that the “best” defibrillation waveform
for the treatment of VF of 4- to 5-min duration would be the one
that is first available.
We have not systematically investigated the differences between
defibrillation waveforms in the management of VF of .5-min
duration. It is very likely that if we administered monophasic
waveform energy doses similar to those used by Sun et al. in their
7-min swine model (4), an average dose approximating 57 J/kg, we
would observe results similar to what they have reported. In our
hospital’s recent six-year clinical experience with out-of-hospital
sudden cardiac death, the largest energy dose used in any patient has
been approximately 33 J/kg delivered with seven countershocks. Since
the energy doses reported by Sun et al. far exceed what is encountered
clinically, our laboratory has no intention of pursuing a similar
experimental design due to its lack of clinical relevance.
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Effectiveness of BiPAP for
Congestive Heart Failure
We were surprised to read the poor results described in the article
by Sharon et al. (1) comparing bilevel positive airway pressure
(BiPAP) ventilation with intravenous isosorbide-dinitrate in pa-
tients with severe pulmonary edema. These findings are in marked
contrast to our own research and experience with this modality
(2–4). We routinely use BiPAP ventilatory support in those
patients with severe pulmonary edema with acute respiratory
failure and imminent need of endotracheal intubation (ETI). Our
success rate at avoiding ETI is generally .90% in patients more
severely ill than those described in the study by Sharon et al. Our
patients receive sublingual nitroglycerin (0.25 mg) along with
sublingual captopril (25 mg) to supplement their respiratory
support. Although intravenous nitrates may be ideal, we find use of
the sublingual route can frequently reverse a patient’s respiratory
distress before intravenous access is even established.
The fact that two dramatically different outcomes are described
for the same intervention may be explained by variations in the
overall treatment of the two populations. Our research has shown
that an independent predictor of BiPAP failure and subsequent
ETI is the use of morphine sulfate. Even moderate amounts such as
those used in the study of Sharon et al. seem to be enough to interfere
with a patient’s abilities to successfully use the BiPAP system.
In treating acute pulmonary edema, high expiratory positive
airway pressures (EPAPs) are required, and we routinely begin our
BiPAP treatments with EPAPs of 8 to 10 cm H2O. Patients
begun on regimens of any lower pressures are titrated up to a level
of $10 cm within 1 min of placement of the nasal mask. In the
study of Sharon et al., patients were begun with EPAPs of 3 cm
H2O and increased by 1 cm every 3 to 4 min to a maximum of
5 cm H2O. Given these parameters, we are surprised that the
authors experienced any success at all. These pressures are far too
low and titration is far too slow for patients with acute respiratory
distress. When applied at the higher pressures, BiPAP-treated
patients demonstrate marked improvements within a few breaths
and are clinically out of danger for ETI within 2 to 3 min.
The presence of positive creatine phosphokinase (CK) markers
in BiPAP-treated patients is an artifact of the rapid drop in left
ventricular wall pressures that occurs when the BiPAP is applied.
There is a washout effect that produces a narrow spike in CK that
exceeds normal thresholds for acute myocardial infarctions, although
the total amount of CK is the same as that which is slowly washed out
over an extended period of time with conventional therapy.
In summary, we believe that the poor outcomes described in the
study of Sharon et al. reflect more problems with the manner in
which the BiPAP was utilized than a failure of the therapy itself.
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REPLY
We have read with great interest the letters by Sacchetti et al. and
Bellone et al. As stated in the introduction of our article, it was also
the impression of all physicians in our institution involved in the
care of patients with pulmonary edema that BiPAP is indeed
helpful in its treatment. However, as is the case in many other
treatment modalities, sometimes the clinical impression does not
hold in the face of rigorous randomized studies. Therefore, we
have tried in the discussion part of our manuscript to suggest a few
mechanisms to explain the failure of BiPAP in our patient
population. What was especially alarming to us was that the results
in the BiPAP arm were worse than our previous experience with
simple medical therapy (without high-dose nitrates). Accordingly,
we decided to discontinue the study prematurely.
Regarding the remarks by Sacchetti et al. and Bellone et al.:
Firstly, it is possible that some of the harmful effect we observed
was due to combination of BiPAP ventilation with morphine
(although it will be very hard from an ethical point of view to deny
patients this small amount of morphine, which is a proven
treatment for pulmonary edema). Secondly, we have chosen
BiPAP rather than CPAP for our study because BiPAP has some
advantage over CPAP by increasing the tidal volume. Also, it was
our subjective impression that patients tolerate BiPAP better than
CPAP. Thirdly, regarding the BiPAP pressures used in our
protocol, it is possible that the moderate pressures we used in the
BiPAP arm were not enough and higher pressures would have
produced a better effect. However, from our experience, it seemed
to us that patients usually do not tolerate higher pressures. Hence,
we started with lower pressures and increased the pressures
gradually. Furthermore, again taking into account that these two
treatment arms were not compared directly, it seems that the
patients in the BiPAP arm of our study faired worse than our
historical controls that underwent exactly the same treatment
without BiPAP. If the assumption of Sacchetti et al. and Bellone
et al. were correct, then we would expect that the results of the
BiPAP arm would be the same as conservative treatment (basically,
if we administered too little BiPAP it should be the same as
administering a lot of oxygen only).
Regarding the pH and PCO2 measurements suggested by
Bellone et al., these were not performed, because the treatment was
administered at the patients’ homes by paramedic units, which are
not equipped for such measurements.
Finally, regarding the early CK peak induced by BiPAP, we are
not aware of any randomized study demonstrating this event.
However, the negative results in our study included not only high
CK but also an increased rate of mechanical ventilation, lower O2
saturation, and increased total events. Furthermore, what we have
observed was that in the BiPAP arm more patients had an increase
in CK into the MI range. In the others we did not observe a CK
increase at all. Therefore, we believe that this cannot be explained
by early CK release, because the patients who did not have an MI
did not have CK release at all.
Since the publication of our study, another randomized study
comparing BiPAP ventilation, with conservative treatment using
oxygen, morphine, furosemide and low-dose nitrates, was pub-
lished (1). In this study, the outcome of patients treated by BiPAP
ventilation was better than in the control arm, although the study
was small (as was our study) and there were significant inequalities
in baseline parameters between the two groups. Therefore, we
believe that the resolution of this important issue will need further,
larger randomized studies.
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